LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...

EMA accepts for review regulatory application of GSK’s Shingrix new prefilled syringe presentation for prevention of shingles: London, UK Wednesday, January 29, 2025, 13:00 Hrs ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of ...

GSK launched Shingrix in China in 2020. Meanwhile, the company is also investing in additional manufacturing capacity to meet the expected demand, with a new plant due to come online in 2024.

On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £500 million from £1.3 billion in the first quarter of 2022, and GSK is expecting the ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...

GSK has announced that a pre-filled syringe version of its Shingrix shingles vaccine has been accepted for review by the ...

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

GSK has announced that the European Medicines Agency (EMA) has accepted its regulatory application for a prefilled syringe presentation of Shingrix ...

GSK had initially entered into a collaboration deal, valued at £2.5 billion for three years until 2026, with Zhifei last year to market Shingrix in mainland China.